Physician

Catherine Nina Kowal, MD

According to 2025 Medicare claims, Catherine Kowal, MD (NPI: 1013909332) practices rheumatology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (NPI: 1598205072; TIN: 831053374) and primary practice location at 34109-0446. Kowal is affiliated with the AdvantagePoint Health Alliance - Western North Carolina, LLC (ACO ID: A5039), participating under the MSSP model.

Kowal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 651 traditional Medicare patients, billed 182,256 HCPCS/CPT codes, and received $1,739,201 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,796 prescription claims across 466 beneficiaries totaling $2,428,226 in drug costs, led by Acthar (Corticotropin). Open Payments data shows 188 records totaling $4,109. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,717,028 to $2,428,226. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	634	65,354	$965,410
2016	646	86,914	$1,207,333
2017	638	126,345	$1,633,619
2018	650	157,633	$2,014,597
2019	657	179,383	$2,116,872
2020	633	186,147	$2,418,317
2021	656	168,727	$2,297,280
2022	661	170,328	$2,030,701
2023	721	213,147	$1,978,805
2024	651	182,256	$1,739,201

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	472	3,785	$1,717,028
2016	486	3,748	$2,030,425
2017	475	3,565	$2,073,601
2018	490	3,360	$2,212,812
2019	471	3,215	$2,985,373
2020	475	3,233	$2,896,202
2021	475	3,320	$2,987,737
2022	481	3,041	$2,978,182
2023	473	2,971	$2,591,890
2024	466	2,796	$2,428,226

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	138	225	$137
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	433	744	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	134	153	$71
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	138	657	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	481	941	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Acthar	Corticotropin	12	336	$535,197
Enbrel Sureclick	Etanercept	62	1,848	$511,594
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	12	336	$228,486
Orencia Clickject	Abatacept	33	980	$202,553
Humira(Cf) Pen	Adalimumab	17	784	$190,495

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	188	$4,109	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Catherine Nina Kowal, MD?

Tedicare shows public-source Medicare data for Catherine Nina Kowal, MD (NPI 1013909332), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Catherine Nina Kowal, MD have ACO affiliation data?

Catherine Nina Kowal, MD is shown with ACO affiliation data for AdvantagePoint Health Alliance - Western North Carolina, LLC (MSSP, ACO ID A5039).

What billing organization is linked to Catherine Nina Kowal, MD?

Catherine Nina Kowal, MD is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (billing NPI 1598205072) in the available physician profile data.

Does Catherine Nina Kowal, MD have Open Payments data?

Catherine Nina Kowal, MD has 188 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.